StocksFundsScreenerSectorsWatchlists
KYMR

KYMR - Kymera Therapeutics, Inc. Stock Price, Fair Value and News

36.32USD-0.08 (-0.22%)Market Closed

Market Summary

KYMR
USD36.32-0.08
Market Closed
-0.22%

KYMR Alerts

  • 4 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

KYMR Stock Price

View Fullscreen

KYMR RSI Chart

KYMR Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-15.1

Price/Sales (Trailing)

28.24

Price/Free Cashflow

-16.17

KYMR Price/Sales (Trailing)

KYMR Profitability

Return on Equity

-37.21%

Return on Assets

-25.52%

Free Cashflow Yield

-6.19%

KYMR Fundamentals

KYMR Revenue

Revenue (TTM)

78.6M

Rev. Growth (Yr)

196.7%

Rev. Growth (Qtr)

912.8%

KYMR Earnings

Earnings (TTM)

-147.0M

Earnings Growth (Yr)

58.79%

Earnings Growth (Qtr)

72.82%

Breaking Down KYMR Revenue

Last 7 days

-7.9%

Last 30 days

-16.5%

Last 90 days

27.5%

Trailing 12 Months

16.8%

How does KYMR drawdown profile look like?

KYMR Financial Health

Current Ratio

4.73

KYMR Investor Care

Shares Dilution (1Y)

10.74%

Diluted EPS (TTM)

-2.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202346.7M51.7M46.8M78.6M
202263.8M56.7M46.0M46.8M
202149.3M64.5M70.3M72.8M
202010.7M18.5M26.3M34.0M
20190002.9M

Tracking the Latest Insider Buys and Sells of Kymera Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
booth bruce
sold
-2,903,340
40.4567
-71,764
-
Mar 14, 2024
booth bruce
sold
-2,229,930
39.9779
-55,779
-
Mar 13, 2024
atlas venture fund x, l.p.
sold
-1,020,420
42.2273
-24,165
-
Mar 13, 2024
booth bruce
sold
-5,880,420
42.2277
-139,255
-
Mar 13, 2024
atlas venture fund x, l.p.
sold
-4,859,990
42.2278
-115,090
-
Mar 12, 2024
atlas venture fund x, l.p.
sold
-1,186,740
41.9773
-28,271
-
Mar 12, 2024
booth bruce
sold
-6,838,810
41.977
-162,918
-
Mar 12, 2024
atlas venture fund x, l.p.
sold
-5,652,070
41.977
-134,647
-
Mar 11, 2024
atlas venture fund x, l.p.
sold
-1,812,590
42.8487
-42,302
-
Mar 11, 2024
atlas venture fund x, l.p.
sold
-380,562
42.8465
-8,882
-

1–10 of 50

Which funds bought or sold KYMR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
reduced
-38.73
-8,016
237,622
-%
Apr 05, 2024
CWM, LLC
new
-
-
-
-%
Apr 05, 2024
GAMMA Investing LLC
added
609
2,775
3,136
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
967
967
-%
Mar 11, 2024
VANGUARD GROUP INC
added
1.84
47,217,500
101,778,000
-%
Mar 04, 2024
CONGRESS ASSET MANAGEMENT CO /MA
added
0.26
525,329
1,153,410
0.01%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
559
31,508,000
34,353,400
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
217,266
480,838
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
302,000
665,000
0.01%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
5.5
65,549,000
135,848,000
0.02%

1–10 of 45

Are Funds Buying or Selling KYMR?

Are funds buying KYMR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KYMR
No. of Funds

Unveiling Kymera Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 01, 2024
baker bros. advisors lp
9.8%
5,997,706
SC 13D
Feb 14, 2024
avoro capital advisors llc
6.8%
3,775,000
SC 13G/A
Feb 13, 2024
vanguard group inc
6.73%
3,997,564
SC 13G/A
Feb 12, 2024
price t rowe associates inc /md/
10.1%
5,999,256
SC 13G/A
Feb 12, 2024
price t rowe associates inc /md/
9.6%
5,340,414
SC 13G/A
Feb 09, 2024
atlas venture fund x, l.p.
8.4%
4,968,114
SC 13G/A
Feb 08, 2024
wellington management group llp
8.68%
4,815,558
SC 13G/A
Jan 29, 2024
blackrock inc.
6.4%
3,566,611
SC 13G/A
Jan 23, 2024
state street corp
3.41%
1,894,279
SC 13G/A
Jan 10, 2024
baker bros. advisors lp
10.8%
5,995,928
SC 13G/A

Recent SEC filings of Kymera Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Apr 01, 2024
3
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
8-K
Current Report
Apr 01, 2024
SC 13D
13D - Major Acquisition
Mar 15, 2024
144
Notice of Insider Sale Intent
Mar 15, 2024
144
Notice of Insider Sale Intent
Mar 15, 2024
4
Insider Trading
Mar 14, 2024
144
Notice of Insider Sale Intent
Mar 14, 2024
144
Notice of Insider Sale Intent
Mar 13, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Kymera Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
2.01% -33.59%
-8.52
5.86
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.7B
1.8B
4.15% -26.04%
-44.64
10.75
76.23% 61.08%
16.5B
2.4B
1.55% -12.37%
98.23
6.81
15.42% 18.43%
12.4B
3.7B
-8.31% -27.12%
20.68
3.34
8.87% 75.42%
MID-CAP
6.5B
396.6M
-12.77% -31.76%
-12.26
16.35
425.83% 18.94%
5.0B
-
-2.52% 80.97%
-7.6
60.35
54.84% -34.79%
3.4B
270.6M
-2.48% 20.65%
-14.28
12.62
440.80% -27.84%
3.2B
240.7M
-23.17% -1.80%
-10.73
13.23
-1.03% -92.09%
2.9B
726.4M
-24.02% -2.94%
-47.88
4.04
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-4.62% -10.82%
25.58
4.59
85.90% -14.05%
620.0M
983.7M
-18.72% -47.64%
-1.14
0.63
-50.36% 17.16%
419.8M
881.7K
-10.95% 416.26%
-9.41
466.16
-77.61% -5.33%
264.3M
4.9M
11.10% 22.40%
-1.96
54.31
-54.97% 51.72%
7.9M
2.1M
91.53% 83.74%
-0.29
2.14
-13.45% 66.37%

Kymera Therapeutics, Inc. News

Latest updates
Defense World51 minutes ago
Seeking Alpha21 Mar 202407:00 am

Kymera Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Revenue912.8%47,8854,72816,5139,46616,1399,55111,5149,62215,27520,33618,51918,70212,78514,5333,2883,4282,189950
Operating Expenses8.0%67,19762,23759,89654,79254,77054,43352,32446,55549,26948,97343,24931,87125,56722,61617,48014,675-12,811
  S&GA Expenses0.8%14,22714,12014,12912,56511,63610,55611,03110,61111,74010,6678,0295,9095,1756,8383,6612,559-1,501
  R&D Expenses10.1%52,97048,11745,76742,22743,13443,87741,29335,94437,52938,30635,22025,96220,39215,77813,81912,116-11,310
Interest Expenses27.0%47.0037.0026.0052.0055.0038.0040.0046.0052.0052.0030.0024.0027.0023.0031.0034.00--
Net Income72.8%-14,368-52,867-38,799-40,928-34,865-43,002-40,257-36,684-33,900-28,582-24,660-13,075-12,685-7,986-13,989-10,932--11,420
Net Income Margin47.7%-1.87*-3.57*-3.05*-3.41*-3.31*-3.35*-2.46*-1.94*-1.38*-1.12*-0.90*-0.97*------
Free Cashflow91.0%-3,580-39,725-46,024-47,977-39,909-35,515-39,720-40,777-38,853-37,566-31,137-22,987------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets4.2%576552582614603638523563606642434465487507117
  Current Assets7.9%40537638541241949440343145154436534130229793.00
    Cash Equivalents35.7%11081.0052.0050.0068.0015677.0034.0048.0015785.0053.0031.0055.0076.00
  Net PPE33.2%48.0036.0027.0017.0013.0013.0013.0012.0012.0012.0012.0011.0011.0011.004.00
Liabilities15.3%18115714715211312612513414615917618920321382.00
  Current Liabilities35.7%86.0063.0055.0062.0071.0091.0088.0088.0093.0094.0010911011110735.00
Shareholder's Equity-0.1%395396435462490513398429460483258275284295-
  Retained Earnings-2.8%-530-516-463-424-383-348-305-265-228-195-166-141-128-116-76.46
  Additional Paid-In Capital1.3%9269149038908798687086986896784254174134112.00
Shares Outstanding5.3%58.0055.0055.0055.0054.0055.0052.0052.0048.0047.0045.0045.00---
Float---1,013---792---1,688----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations125.4%8,045-31,647-35,256-43,968-39,536-34,269-38,985-40,295-38,352-37,260-30,511-22,823-20,068131,667-11,412-12,057--
  Share Based Compensation-6.5%10,89811,65511,1809,3858,9099,0769,6227,8738,6787,3965,7263,1721,8272,328664371--
Cashflow From Investing-68.7%18,95260,51135,83924,584-49,666-37,48181,80325,863-68,019-136,86260,72344,323-3,990-334,321-46,874-37,403--
Cashflow From Financing1038.8%1,934-2061,3051,1591,953150,4973641852,054246,0391,592595270196,275-40393,120--

KYMR Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Collaboration Revenue—from related party$ 78,592$ 46,826$ 72,832
Revenue from Contract with Customer, Product and Service [Extensible List]Collaboration Revenues From Related Party [Member]Collaboration Revenues From Related Party [Member]Collaboration Revenues From Related Party [Member]
Operating expenses:   
Research and development$ 189,081$ 164,248$ 137,017
General and administrative55,04143,83436,345
Total operating expenses244,122208,082173,362
Loss from operations(165,530)(161,256)(100,530)
Other income (expense):   
Interest and other income18,7646,624488
Interest and other expense(196)(176)(175)
Total other income18,5686,448313
Net loss(146,962)(154,808)(100,217)
Other comprehensive loss:   
Unrealized (loss) gain on marketable securities4,397(4,289)(532)
Total comprehensive loss(142,565)(159,097)(100,749)
Reconciliation of net loss to net loss attributable to common stockholders:   
Net Income (Loss)(146,962)(154,808)(100,217)
Net loss attributable to common stockholders$ (146,962)$ (154,808)$ (100,217)
Net loss per share, basic$ (2.52)$ (2.87)$ (2.09)
Net loss per share, diluted$ (2.52)$ (2.87)$ (2.09)
Weighted average common shares outstanding, diluted58,365,49953,933,22947,989,023
Weighted average common shares outstanding, basic58,365,49953,933,22947,989,023

KYMR Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 109,966$ 68,395
Marketable securities (Note 4)264,915338,771
Accounts Receivable15,0000
Contract assets-due from related party3,7622,537
Prepaid expenses and other current assets11,6749,713
Total current assets405,317419,416
Marketable securities, non-current (Note 4)61,434152,328
Property and equipment, net (Note 6)48,13413,334
Right-of-use assets, operating leases52,9458,909
Other non-current assets2,1183,017
Restricted cash5,8116,130
Total assets575,759603,134
Current liabilities:  
Accounts payable7,0754,335
Accrued expenses (Note 8)33,86427,502
Deferred revenue37,88335,260
Operating lease liabilities5,0682,535
Finance lease liabilities1,2771,408
Other current liabilities524303
Total current liabilities85,69171,343
Non-current liabilities  
Deferred revenue, net of current portion16,76828,000
Operating lease liabilities, net of current portion77,02812,146
Finance lease liabilities, net of current portion1,3011,246
Other non-current liabilities0248
Total liabilities180,788112,983
Commitments and contingencies (Note 9)
Stockholders' equity:  
Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2022 and 2021, 55,039,380 and 51,573,924 shares issued at December 31, 2022 and 2021, respectively; 55,039,380 and 51,536,181 shares outstanding at December 31, 2022 and 2021, respectively66
Additional paid-in capital926,269878,884
Accumulated deficit(530,752)(383,790)
Accumulated other comprehensive loss(552)(4,949)
Total stockholders' equity394,971490,151
Total liabilities and stockholders' equity$ 575,759$ 603,134
KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEkymeratx.com
 INDUSTRYBiotechnology
 EMPLOYEES181

Kymera Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Kymera Therapeutics, Inc.? What does KYMR stand for in stocks?

KYMR is the stock ticker symbol of Kymera Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kymera Therapeutics, Inc. (KYMR)?

As of Mon Apr 08 2024, market cap of Kymera Therapeutics, Inc. is 2.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KYMR stock?

You can check KYMR's fair value in chart for subscribers.

What is the fair value of KYMR stock?

You can check KYMR's fair value in chart for subscribers. The fair value of Kymera Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kymera Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KYMR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kymera Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether KYMR is over valued or under valued. Whether Kymera Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Kymera Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KYMR.

What is Kymera Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 08 2024, KYMR's PE ratio (Price to Earnings) is -15.1 and Price to Sales (PS) ratio is 28.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KYMR PE ratio will change depending on the future growth rate expectations of investors.